All In Biotech

Drug Trial Radar · NCT04886739

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

Safety and Effectiveness of CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea: A Randomized, Double-Blind, Vehicle-Controlled Proof of Concept Study

Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

May 7, 2021

Primary completion

Dec 22, 2021

Study completion Dec 22, 2021

Sponsor

Lead sponsor
CAGE Bio Inc.Industry
Sponsor type
Industry
Collaborators
ethica Clinical Research Inc.
First posted
May 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12. Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.

Conditions

  • Rosacea

Interventions

  • CGB-400Drug

    Topical gel

  • Vehicle GelDrug

    Topical gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Inflammatory Lesion CountTime frame: Week 12
  2. Investigator Global Assessment (IGA)Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cage Bio Investigative Site 1

    Fremont, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.